Trials / Recruiting
RecruitingNCT07219030
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
A Phase 1, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Emraclidine Following Multiple Ascending Oral Doses in Healthy Elderly Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 65 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emraclidine | Oral tablets |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2025-10-08
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2025-10-21
- Last updated
- 2025-11-10
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT07219030. Inclusion in this directory is not an endorsement.